Opinion statement
Viral infections often affect the heart. In the majority of cases, the course of the disease is benign and patients recover spontaneously. However, viral infection may persist and lead to acute cardiac failure or progress to dilated cardiomyopathy. Viral infections are considered to be the most common causes of myocarditis. There is evidence that intramyocardial viral persistence is associated with progressive ventricular dysfunction, even when the infiltrate is sparse or missing. The diagnosis of viral myocarditis necessitates the detection of viral genome by molecular biology techniques and the evaluation of myocardial inflammation by the immunohistochemistry on endomyocardial biopsy samples. Autoreactive myocarditis can also only be diagnosed by endomyocardial biopsy. Infiltration of leukocytes and a negative polymerase chain reaction on microbial agents are their hallmarks. Apart from symptomatic or supportive therapy, etiologic treatment strategies have to address the underlying causative virus or the autoimmune process. In symptomatic or deteriorating patients, targeted antiviral therapy is a reasonable algorithm to eradicate the virus, which will contribute to resolving inflammation or apoptosis, thus confining myocardial damage. The Marburg registry favors intravenous immunoglobulin treatment in biopsy-proven adenovirus and parvovirus B19 myocarditis combined with optimal conventional therapy to achieve virus clearance. In fulminant myocarditis, biopsy is mandatory to identify giant cell myocarditis and cardiac sarcoidosis to be treated by immunosuppression. In cardiogenic shock, the use of mechanical circulatory support by means of a ventricular assist device as a bridge to recovery may be a lifesaving approach. In perimyocarditis with dominant pericardial affection, colchicine over a period of 1 to 6 months can dissolve the pericardial effusion effectively in more than 80% of cases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Richardson P, McKenna W, Bristow M, et al.: Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996, 93:841–842.
Maisch B, Bültman B, Factor S, et al.: World Heart Federation consensus conferences’ definition of inflammatory cardiomyopathy (myocarditis): report from two expert committees on histology and viral cardiomyopathy. Heartbeat 1999, 4:3–4.
Pankuweit S, Portig I, Eckhardt H, et al.: Prevalence of viral genome in endomyocardial biopsies from patients with inflammatory heart muscle disease. Herz 2000, 25:221–226.
Fujioka S, Kitaura Y, Ukimura A, et al.: Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000, 36:1920–1926.
Pankuweit S, Baandrup U, Moll R, et al.: Prevalence of parvovirus B19 genome in endomyocardial biopsy specimen. Hum Pathol 2003, 34:80–86.
Kühl U, Pauschinger M, Bock T, et al.: Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 2003, 108:945–950.
Kühl U, Pauschinger M, Noutsias M, et al.: High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 2005, 111:887–893.
Kühl U, Pauschinger M, Seeberg B, et al.: Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005, 112:1965–1970.
Maisch B, Richter A, Koelsch S, et al.: Management of patients with suspected (peri-) myocarditis and inflammatory dilated cardiomyopathy. Herz 2006, 31:881–890.
Maisch B, Ristic A, Hufnagel G, et al.: Pathophysiology of viral myocarditis. The role of humoral immune response. Cardioasc Pathol 2002, 11:112–122.
Pankuweit S, Ruppert V, Maisch B: Inflammation in dilated cardiomyopathy. Herz 2004, 29:788–793.
Mason JW: Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res 2003, 60:5–10.
Aretz HT, Billingham ME, Edwards WD, et al.: Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987, 1:3–14.
Matsumori A: Hepatitis C virus and cardiomyopathy. Herz 2000, 25:249–254.
Matsumori A, Yutani C, Ikeda Y, et al.: Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 2000, 80:1137–1142.
Matsumori A: Role of hepatitis C virus in cardiomyopathies. Ernst Schering Res Found Workshop 2006, 55:99–120.
Drory Y, Turetz Y, Hiss Y, et al.: Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991, 68:1388–1392.
Constanzo-Nordin MR, O’Connell JB, Subramanian R, et al.: Myocarditis confirmed by biopsy presenting as acute myocardial infarction. Br Heart J 1985, 53:25–29.
Lauer B, Niederau C, Kuhl U, et al.: Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1977, 30:1354–1359.
Karjalainen J, Viitasalo M, Kala R, et al.: 24-hour electrocardiographic recordings in mild acute infectious myocarditis. Ann Clin Res 1984, 16:34–39.
Tai YT, Lau CP, Fong PC, et al.: Incessant automatic ventricular tachycardia complicating acute Coxsackie B myocarditis. Cardiology 1992, 30:339–344.
Friedrich MG, Strohm O, Schulz-Menger J, et al.: Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998, 97:1802–1809.
Ilback NG, Fohlman J, Friman G: Exercise in Coxsackie B3 myocarditis: effects on heart lymphocyte subpopulations and the inflammatory reaction. Am Heart J 1989, 117:1298–1302.
Hosenpud JD, Campbell SM, Niles NR, et al.: Exercise induced augmentation of cellular and humoral autoimmunity associated with increased cardiac dilatation in experimental autoimmune myocarditis. Cardiovasc Res 1987, 21:217–222.
Takeda Y, Yasuda S, Miyazaki S, et al.: High-dose immunoglobulin G therapy for fulminant myocarditis. Jap Circ J 1998, 62:871–872.
Nigro G, Bastianon V, Coloridi V, et al.: Human parvovirus B19 infection in infancy with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 2000, 31:65–69.
Shioji K, Matsuura Y, Iwase T, et al.: Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thioredoxin: a case report. Circulation J 2002, 66:977–980.
Drucker NA, Coland SD, Lewis AB, et al.: Gammaglobulin treatment of acute myocarditis in the pediatric population. Circulation 1994, 89:252–257.
McNamara DM, Rosenblum WD, Janosko KM, et al.: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997, 95:2476–2478.
McNamara DM, Holubkov R, Randall CS, et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254–2259.
Maisch B, Hufnagel G, Kölsch S, et al.: Treatment of inflmmatory dilated cardiomyopathy and (peri) myocarditis with immunosuppression and intravenous immunoglobulins. Herz 2004, 29:624–636.
Maisch B, Hufnagel G, Schoenian U, Hengstenberg C: The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). Eur Heart J 1995, 16(Suppl O):173–175.
Hufnagel G, Pankuweit S, Richter A, et al.: The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz 2000, 25:279–285.
Kühl U, Paischinger M, Schwimmbeck PL, et al.: Interferonbeta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003, 107:2793–2798.
Mason JW, O’Connell JB, Herskowitz A, et al.: A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995, 333:269–275.
Frustaci A, Chimenti C, Calabrese F, et al.: Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003, 107:857–863.
O’Connell JB, Dec GW, Goldenberg IF, et al.: Results of heart transplantation for active lymphocytic myocarditis. J Heart Transplant 1990, 9:351–356.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karatolios, K., Pankuweit, S. & Maisch, B. Diagnosis and treatment of myocarditis: The role of endomyocardial biopsy. Curr Treat Options Cardio Med 9, 473–481 (2007). https://doi.org/10.1007/s11936-007-0042-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11936-007-0042-1